

# Tomasz M Beer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/287442/publications.pdf>

Version: 2024-02-01

165  
papers

20,165  
citations

31976

53  
h-index

10734

138  
g-index

172  
all docs

172  
docs citations

172  
times ranked

18300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	27.0	2,456
2	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	1.6	1,960
3	Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. <i>Science</i> , 2009, 324, 787-790.	12.6	1,955
4	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
5	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	27.0	1,042
6	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1â€“2 study. <i>Lancet</i> , The, 2010, 375, 1437-1446.	13.7	972
7	Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. <i>Nature Medicine</i> , 2012, 18, 1359-1368.	30.7	682
8	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	1.6	577
9	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.	1.6	477
10	How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30. <i>Journal of Clinical Oncology</i> , 2004, 22, 3485-3490.	1.6	475
11	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	28.9	459
12	Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer. <i>Cancer Research</i> , 2010, 70, 7992-8002.	0.9	313
13	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. <i>European Urology</i> , 2017, 71, 151-154.	1.9	306
14	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 52810-52817.	1.8	305
15	Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. <i>Journal of Clinical Oncology</i> , 2007, 25, 669-674.	1.6	296
16	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	288
17	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
18	Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 123-128.	1.6	245

#	ARTICLE	IF	CITATIONS
19	Statins and Prostate Cancer Risk: A Case-Control Study. <i>American Journal of Epidemiology</i> , 2005, 162, 318-325.	3.4	217
20	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	21.4	198
21	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 509-521.	10.7	174
22	Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. <i>Seminars in Oncology</i> , 2001, 28, 49-55.	2.2	148
23	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. <i>European Urology</i> , 2011, 60, 279-290.	1.9	130
24	Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4558-4567.	7.0	128
25	High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. <i>Cancer</i> , 2003, 97, 1217-1224.	4.1	120
26	A Phase I trial of pulse calcitriol in patients with refractory malignancies. <i>Cancer</i> , 2001, 91, 2431-2439.	4.1	116
27	Testosterone Loss and Estradiol Administration Modify Memory in Men. <i>Journal of Urology</i> , 2006, 175, 130-135.	0.4	110
28	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. <i>European Urology</i> , 2013, 63, 717-723.	1.9	104
29	Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project. <i>Journal of Cancer Survivorship</i> , 2016, 10, 633-644.	2.9	104
30	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	1.9	104
31	Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. <i>Cancer</i> , 2008, 113, 2205-2214.	4.1	102
32	Resistance Training Reduces Disability in Prostate Cancer Survivors on Androgen Deprivation Therapy: Evidence From a Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, 7-14.	0.9	102
33	Calcitriol in cancer treatment: from the lab to the clinic. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 373-81.	4.1	100
34	C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer. <i>Cancer</i> , 2008, 112, 2377-2383.	4.1	98
35	CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. <i>Prostate</i> , 2010, 70, 433-442.	2.3	98
36	Improved Detection of Prostate Cancer Using Classification and Regression Tree Analysis. <i>Journal of Clinical Oncology</i> , 2005, 23, 4322-4329.	1.6	95

#	ARTICLE	IF	CITATIONS
37	Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. <i>Cancer</i> , 2008, 112, 326-330.	4.1	91
38	Skeletal Response to Resistance and Impact Training in Prostate Cancer Survivors. <i>Medicine and Science in Sports and Exercise</i> , 2014, 46, 1482-1488.	0.4	84
39	High dose calcitriol may reduce thrombosis in cancer patients. <i>British Journal of Haematology</i> , 2006, 135, 392-394.	2.5	76
40	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 81, 228-236.	2.8	76
41	Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. <i>European Urology</i> , 2020, 78, 347-357.	1.9	75
42	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 675-683.	1.9	70
43	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	5.9	70
44	Association of codon 72 polymorphism of p53 with lower prostate cancer risk. <i>Prostate</i> , 2001, 49, 263-266.	2.3	69
45	Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1414-1419.	2.6	66
46	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	3.9	66
47	American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5313-5318.	1.6	65
48	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1532-1542.	10.7	65
49	Genetic polymorphisms in head and neck cancer risk. <i>Head and Neck</i> , 2000, 22, 609-617.	2.0	64
50	Molecular Alterations in Prostate Carcinomas that Associate with <i>In vivo</i> Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15. <i>Clinical Cancer Research</i> , 2007, 13, 5825-5833.	7.0	60
51	Histologic Changes Associated With Neoadjuvant Chemotherapy Are Predictive of Nodal Metastases in Patients With High-Risk Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2010, 133, 654-661.	0.7	58
52	C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 33-37.	1.6	57
53	The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 3562-3570.	7.0	55
54	Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. <i>Seminars in Oncology</i> , 2001, 28, 49-55.	2.2	53

#	ARTICLE	IF	CITATIONS
55	Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. <i>Prostate</i> , 2013, 73, 1028-1037.	2.3	52
56	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. <i>Molecular Cancer Research</i> , 2019, 17, 1235-1240.	3.4	51
57	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
58	Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate Cancer. <i>Oncology Nursing Forum</i> , 2015, 42, 348-356.	1.2	50
59	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021, 13, 3501.	3.7	50
60	Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. <i>Investigational New Drugs</i> , 2007, 25, 565-570.	2.6	49
61	Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. <i>Cancer</i> , 2005, 103, 717-723.	4.1	48
62	Prostate cancer survival is dependent on season of diagnosis. <i>Prostate</i> , 2007, 67, 1362-1370.	2.3	48
63	Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. <i>Cancer Causes and Control</i> , 2010, 21, 1297-1303.	1.8	48
64	Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients Aged ≥ 70 Years Compared with Patients Aged < 70 Years. <i>Clinical Prostate Cancer</i> , 2003, 2, 167-172.	2.1	47
65	Acupuncture for Hot Flashes in Patients With Prostate Cancer. <i>Urology</i> , 2010, 76, 1182-1188.	1.0	47
66	Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 7794-7799.	7.0	46
67	Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 103-109.	1.9	46
68	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	7.1	46
69	High-Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 535-541.	1.3	44
70	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 52-63.	7.0	44
71	Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 581-587.	2.3	42
72	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	1.9	42

#	ARTICLE	IF	CITATIONS
73	ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. <i>BJU International</i> , 2005, 96, 508-513.	2.5	40
74	HIGH DOSE PULSE CALCITRIOL, DOCETAXEL AND ESTRAMUSTINE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: A PHASE I/II STUDY. <i>Journal of Urology</i> , 2005, 174, 888-892.	0.4	40
75	Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. <i>Nature Communications</i> , 2018, 9, 4972.	12.8	40
76	Long-term Safety and Antitumor Activity in the Phase 1â€² Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2015, 68, 795-801.	1.9	39
77	Calcitriol in the treatment of prostate cancer. <i>Anticancer Research</i> , 2006, 26, 2647-51.	1.1	39
78	A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. <i>Anti-Cancer Drugs</i> , 2010, 21, 433-438.	1.4	38
79	Phase 1/2 study of preoperative docetaxel and mitoxantrone for highâ€­risk prostate cancer. <i>Cancer</i> , 2010, 116, 1699-1708.	4.1	38
80	Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 399-403.	3.4	38
81	Development of weekly high-dose calcitriol based therapy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 399-405.	1.6	37
82	Docetaxel (Taxotereâˆ®) in the treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 261-268.	2.4	37
83	The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer. <i>Cancer</i> , 2006, 107, 489-496.	4.1	37
84	A phase II study of highâ€­dose calcitriol combined with mitoxantrone and prednisone for androgenâ€­independent prostate cancer. <i>BJU International</i> , 2008, 102, 1601-1606.	2.5	35
85	Implementing a comprehensive translational oncology platform: from molecular testing to actionability. <i>Journal of Translational Medicine</i> , 2018, 16, 358.	4.4	35
86	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	2.9	35
87	Polymorphisms of GSTT1 and related genes in head and neck cancer risk. <i>Head and Neck</i> , 2004, 26, 63-70.	2.0	34
88	Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. <i>Prostate</i> , 2000, 45, 184-193.	2.3	33
89	Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 1306-1311.	7.0	33
90	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , 2006, 106, 2624-2629.	4.1	33

#	ARTICLE	IF	CITATIONS
91	Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. <i>Urology</i> , 2004, 63, 342-347.	1.0	31
92	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
93	PROGNOSTIC VALUE OF ANEMIA IN NEWLY DIAGNOSED METASTATIC PROSTATE CANCER: A MULTIVARIATE ANALYSIS OF SOUTHWEST ONCOLOGY GROUP STUDY 8894. <i>Journal of Urology</i> , 2004, 172, 2213-2217.	0.4	30
94	Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes. <i>PLoS ONE</i> , 2014, 9, e104271.	2.5	30
95	CTâ€“Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1073-1081.e1.	0.5	30
96	Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. <i>World Journal of Urology</i> , 2005, 23, 28-32.	2.2	29
97	Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 254-259.	1.6	29
98	Phase II Study of Abarelix Depot for Androgen Independent Prostate Cancer Progression During Gonadotropin-Releasing Hormone Agonist Therapy. <i>Journal of Urology</i> , 2003, 169, 1738-1741.	0.4	28
99	Southwest Oncology Group Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium that Progressed After Platinum-Based Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 36-39.	1.9	27
100	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	1.9	27
101	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. <i>European Journal of Cancer</i> , 2017, 87, 21-29.	2.8	26
102	Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?. <i>Supportive Care in Cancer</i> , 2022, 30, 1903-1906.	2.2	26
103	Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. <i>Journal of Medical Internet Research</i> , 2020, 22, e19238.	4.3	25
104	Cyclooxygenaseâ€2 (<sc>COX</sc>â€2) inhibition for prostate cancer chemoprevention: doubleâ€blind randomised study of preâ€prostatectomy celecoxib or placebo. <i>BJU International</i> , 2017, 119, 709-716.	2.5	24
105	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 71447-71455.	1.8	23
106	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. <i>European Urology Oncology</i> , 2019, 2, 677-684.	5.4	22
107	Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. <i>Cancer</i> , 2004, 100, 758-763.	4.1	21
108	Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. <i>Journal of Lipid Research</i> , 2006, 47, 349-355.	4.2	21

#	ARTICLE	IF	CITATIONS
109	Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1306-1312.	7.0	19
110	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>JAMA Oncology</i> , 2020, 6, 217.	7.1	18
111	Diethylstilbestrol and docetaxel. <i>Cancer</i> , 2007, 110, 996-1002.	4.1	17
112	Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer. <i>Urology</i> , 2013, 82, 410-415.	1.0	17
113	Prostate Cancer-associated Gene Expression Alterations Determined from Needle Biopsies. <i>Clinical Cancer Research</i> , 2009, 15, 3135-3142.	7.0	15
114	Effect of Calcitriol on Prostate-Specific Antigen In vitro and in Humans. <i>Clinical Cancer Research</i> , 2006, 12, 2812-2816.	7.0	14
115	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	3.0	14
116	Novel blood-based early cancer detection: diagnostics in development. <i>American Journal of Managed Care</i> , 2020, 26, S292-S299.	1.1	14
117	Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 2225-32.	2.5	14
118	Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents. <i>Drugs and Aging</i> , 2014, 31, 873-882.	2.7	13
119	Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e217-e221.	1.9	13
120	Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?. <i>European Journal of Cancer</i> , 2005, 41, 954-964.	2.8	12
121	Prostate Cancer and Vitamin D: What Does the Evidence Really Suggest?. <i>Urologic Clinics of North America</i> , 2011, 38, 333-342.	1.8	12
122	Review of Exercise Studies in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy Calls for an Aggressive Research Agenda to Generate High-Quality Evidence and Guidance for Exercise As Standard of Care. <i>Journal of Clinical Oncology</i> , 2014, 32, 2518-2519.	1.6	12
123	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-supported West Coast Prostate Cancer Dream Team. <i>European Urology Focus</i> , 2016, 2, 469-471.	3.1	12
124	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	2.8	12
125	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study. <i>Journal of Clinical Oncology</i> , 2012, 30, 25-25.	1.6	11
126	Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 120-126.	1.4	10

#	ARTICLE	IF	CITATIONS
127	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4616-4624.	7.0	10
128	Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6204-6214.	7.0	10
129	Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e191-e198.	1.9	9
130	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11257.	1.0	9
131	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. <i>European Journal of Cancer</i> , 2022, 170, 285-295.	2.8	9
132	SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: A RARE COMPLICATION OF PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 166, 1386-1386.	0.4	8
133	The hazards of intermediate endpoints. <i>Cancer</i> , 2007, 110, 1877-1879.	4.1	7
134	Personalizing prostate cancer therapy: the way forward. <i>Drug Discovery Today</i> , 2014, 19, 1483-1487.	6.4	7
135	Study protocol for the Exercising Together© trial: a randomized, controlled trial of partnered exercise for couples coping with cancer. <i>Trials</i> , 2021, 22, 579.	1.6	7
136	Protocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer. <i>Trials</i> , 2021, 22, 775.	1.6	7
137	Parenteral Estrogens for Prostate Cancer: Can a New Route of Administration Overcome Old Toxicities?. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 198-205.	1.9	6
138	The role of C-reactive protein in prostate cancer. <i>Cancer</i> , 2013, 119, 3262-3264.	4.1	6
139	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.	3.9	6
140	Darbepoetin Alfa Administered Every 4 Weeks for Anemia in Patients with Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 329-333.	1.9	5
141	Optimal timing of chemotherapy in androgen independent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 97-100.	1.6	5
142	Prevention and management of prostate cancer chemotherapy complications. <i>Urologic Clinics of North America</i> , 2004, 31, 367-378.	1.8	4
143	Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. <i>Anti-Cancer Drugs</i> , 2006, 17, 1075-1079.	1.4	4
144	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 931.e9-931.e16.	1.6	4

#	ARTICLE	IF	CITATIONS
145	Quality of Life of Prostate Cancer Survivors Participating in a Remotely Delivered Web-Based Behavioral Intervention Pilot Randomized Trial. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542110635.	2.0	4
146	Examining developments in multicancer early detection: highlights of new clinical data from recent conferences. <i>American Journal of Managed Care</i> , 2021, 27, S347-S355.	1.1	4
147	Allogeneic stem-cell transplantation in renal-cell carcinoma. <i>Current Oncology Reports</i> , 2001, 3, 433-437.	4.0	3
148	A Phase I trial of pulse calcitriol in patients with refractory malignancies. <i>Cancer</i> , 2001, 91, 2431-2439.	4.1	3
149	A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer Therapy. <i>Reviews in Urology</i> , 2003, 5 Suppl 3, S38-44.	0.9	3
150	Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. <i>Current Urology Reports</i> , 2002, 3, 232-238.	2.2	2
151	Toward predictors of survival in castration-resistant prostate cancer. <i>Cancer</i> , 2011, 117, 3882-3884.	4.1	2
152	Bevacizumab and thrombosis: Some answers but questions remain. <i>Cancer</i> , 2015, 121, 975-977.	4.1	2
153	Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2958-2960.	1.6	2
154	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	3.9	2
155	Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 190-195.	1.3	2
156	Vitamin D and Prostate Cancer. , 2011, , 221-249.		1
157	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 51-61.	2.4	1
158	Combining options in metastatic prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 569-570.	3.8	1
159	SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION:. <i>Journal of Urology</i> , 2001, , 1386.	0.4	1
160	Carbohydrate-conjugated fluorescent silica nanoprobe for selective detection of galectin-1 and prostate cancer cells. <i>Science Letters Journal</i> , 2015, 4, .	0.0	1
161	Simplified Assessment of Compliance With and Acceptability of Dietary Calcium Restriction in Patients Treated With High Dose Calcitriol for Advanced Cancer. <i>Topics in Clinical Nutrition</i> , 2003, 18, 61-70.	0.4	0
162	Vitamin D Analogs and Their Role in Prostate Cancer. <i>Translational Medicine Series</i> , 2006, , 257-279.	0.0	0

#	ARTICLE	IF	CITATIONS
163	Calcitriol and Vitamin D Analogs. , 2010, , 287-302.		0
164	The safety of prostate biopsy procedures in the research setting: A 10-year multicenter experience.. Journal of Clinical Oncology, 2012, 30, 87-87.	1.6	0
165	HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1 $\alpha$ -Inhibition. Frontiers in Cell and Developmental Biology, 2021, 9, 724059.	3.7	0